Hematological response to the new synthetic muramyl dipeptide derivative muroctasin after chemotherapy in patients with malignant lymphoma. A randomized crossover trial.

Abstract	A randomized crossover trial was performed in 20 patients receiving chemotherapy for malignant lymphoma. N2-[(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl]-N6-stearoyl-L-lysine (MDP-Lys(L18), muroctasin) at a dose of 200 micrograms was subcutaneously administered after one of two cycles of the same protocol. The administration was started on day 4 after the start of chemotherapy and continued for 10 days. The mean length from the start of chemotherapy to nadir of white blood cell (WBC) was not significantly different between the control and muroctasin cycles. The mean WBC and neutrophil counts at nadir of the control cycle were significantly lower than those at the same point of muroctasin cycle, respectively. A positive effect of muroctasin cycle, defined as WBC count at nadir being increased by 1,000/mm3, WBC count being increased by 1,000/mm3 on two points examined after nadir, or faster reach to nadir and faster recovery to normal range of WBC than in the control cycle, was observed in 7 (35%) of 20 patients. On the other hand, only one (5%) patient showed a superiority of the control cycle over the muroctasin cycle. Toxic effects of muroctasin were observed in 34.8% of patients, but were tolerable for most patients. These results show that muroctasin has a clinical efficacy in the restoration of leukopenia after chemotherapy.
Authors	A Hiraoka, T Masaoka, T Satoh, K Ota, A Oyama, A Horiuchi, H Hasegawa, K Nagai, M Kosaki, A Kanemaru
Journal	Arzneimittel-Forschung (Arzneimittelforschung) Vol. 38 Issue 10 Pg. 1499-501 (Oct 1988) ISSN: 0004-4172 [Print] Germany
PMID	3058133 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References	Acetylmuramyl-Alanyl-Isoglutamine romurtide
Topics	Acetylmuramyl-Alanyl-Isoglutamine (administration & dosage, analogs & derivatives, pharmacology, therapeutic use) Adult Aged Clinical Trials as Topic Female Hodgkin Disease (drug therapy) Humans Injections, Subcutaneous Leukocyte Count Leukocytes (drug effects) Lymphoma, Non-Hodgkin (drug therapy) Male Middle Aged Neutrophils (drug effects) Random Allocation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!